Orca Bio

Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for cancer and autoimmune diseases. The company's investigational allogeneic T-cell immunotherapies use regulatory T cells. Orca Bio's TREGZI™ received FDA approval as the first precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies.